Sucampo Pharma Americas, LLC

Quick facts

Phase 3 pipeline

• Cohort 1: Lubiprostone Capsule, Fasted · Gastroenterology
  Lubiprostone activates ClC-2 chloride channels in the intestinal epithelium to increase intestinal fluid secretion and promote bowel motility.
• Lubiprostone 24 · Gastroenterology
  Lubiprostone is a ClC-2 chloride channel activator that increases intestinal fluid secretion and promotes bowel motility to relieve constipation.

Phase 2 pipeline

• Non-steroidal anti-inflammatory drug

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Sucampo Pharma Americas, LLC portfolio CI brief
• Sucampo Pharma Americas, LLC pipeline updates RSS